

SHARED CARE FRAMEWORK

**The Pan Mersey Area Prescribing Committee recommends
the prescribing of GUANFACINE (Intuniv[®]▼) for ADHD
in accordance with NICE NG87.**

SHARED CARE

1. Background

NHS Halton CCG for the treatment of adults only
NHS Knowsley CCG for the treatment of adults only
NHS St Helens CCG for the treatment of adults only
NHS Warrington CCG for the treatment of adults only
NHS Wirral CCG for the treatment of adults only

This shared care framework aims to provide clarity on the responsibilities of all professionals involved in commissioning and prescribing across primary, secondary and tertiary care. Good organisation of care across the interface between primary and secondary/tertiary care is crucial in ensuring that patients receive high quality care – and in making the best use of clinical time and NHS resources in all care.

Attention deficit hyperactivity disorder (ADHD) is a chronic, neurodevelopmental disorder associated with inattention, hyperactivity and impulsiveness. The National Institute for Health and Clinical Excellence (NICE) issued a clinical guideline, Attention Deficit Hyperactivity Disorder: diagnosis and management (NG87) in 2018. This document advises that treatment for ADHD should only be initiated by a healthcare professional with expertise in ADHD and should be based on a comprehensive assessment and diagnosis. Continued prescribing and monitoring of drug therapy may be performed by the primary care clinicians, under shared care arrangements.

NICE NG87 states: Offer guanfacine to children aged 5 years and over and young people if they cannot tolerate methylphenidate or lisdexamfetamine or their symptoms have not responded to separate 6-week trials of lisdexamfetamine and methylphenidate, having considered alternative preparations and adequate doses.

Symptoms of ADHD can persist into adulthood in about two thirds of all patients. For patients transitioning into adulthood, specialists should ensure appropriate arrangements are made for referral into adult services. In such circumstances a new shared care agreement will need to be made between the primary care clinician and the new specialist provider.

Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist or psychiatrist.

	<p>Guanfacine is a selective central alpha 2A-adrenergic receptor agonist and it is a non-stimulant. Preclinical research suggests guanfacine modulates signalling in the prefrontal cortex and basal ganglia through direct modification of synaptic noradrenalin transmission at the alpha 2- adrenergic receptors.</p>																		
2. Licensed indications	<p>Guanfacine is indicated for the treatment of ADHD in children and adolescents 6 – 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. It must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.</p>																		
3. Locally agreed off-label use	<p>This document supports the following off label uses:</p> <ul style="list-style-type: none"> • Continuing treatment in adults from 18 years old and above whose symptoms persist into adulthood and who have shown clear benefit from treatment • Children aged 6 years old and above weighing less than 25kg • Children aged 5-6 years 																		
4. Initiation and ongoing dose regime	<p>Transfer of monitoring and prescribing to primary care is normally after 3 months if the request to prescribe is accepted. This will be when the dose and monitoring are stable. The duration of treatment will be determined by the specialist based on clinical response and tolerability.</p> <p>Dosing information</p> <p>All dose adjustments will be the responsibility of the initiating specialist unless directions have been discussed and agreed with the primary care clinician. For all patients, the recommended starting dose is 1 mg of guanfacine, taken orally once a day.</p> <p>The dose may be adjusted in increments of not more than 1 mg per week. The initial dose should be titrated against symptoms and adverse effects in line with the BNF or BNF for Children until dose optimisation is achieved, that is, reduced symptoms, positive behaviour change, improvements in education, employment and relationships, with tolerable adverse effects².</p> <p>The recommended maintenance dose range is 0.05 - 0.12 mg/kg/day.</p> <p>The recommended dose titration for children and adolescents is provided below (see under specialist initiation and titration). Dose adjustments (increase or decrease) to a maximum tolerated dose within the recommended optimal weight-adjusted dose range based upon clinical judgement of response and tolerability may occur at any weekly interval after the initial dose.</p> <table border="1"> <thead> <tr> <th>Age</th> <th>Weight Group</th> <th>Recommended max dosage frequency</th> </tr> </thead> <tbody> <tr> <td>6 – 12 years</td> <td><34kg</td> <td>4mg once daily</td> </tr> <tr> <td rowspan="4">13 – 17 years</td> <td>34 – 41.4kg</td> <td>4mg once daily</td> </tr> <tr> <td>41.5 – 49.4kg</td> <td>5mg once daily</td> </tr> <tr> <td>49.5 – 58.4kg</td> <td>6mg once daily</td> </tr> <tr> <td>58.5kg and above</td> <td>7mg once daily</td> </tr> <tr> <td>Adult aged 18 years and over</td> <td></td> <td>Continue treatment at the stabilised dose</td> </tr> </tbody> </table>	Age	Weight Group	Recommended max dosage frequency	6 – 12 years	<34kg	4mg once daily	13 – 17 years	34 – 41.4kg	4mg once daily	41.5 – 49.4kg	5mg once daily	49.5 – 58.4kg	6mg once daily	58.5kg and above	7mg once daily	Adult aged 18 years and over		Continue treatment at the stabilised dose
Age	Weight Group	Recommended max dosage frequency																	
6 – 12 years	<34kg	4mg once daily																	
13 – 17 years	34 – 41.4kg	4mg once daily																	
	41.5 – 49.4kg	5mg once daily																	
	49.5 – 58.4kg	6mg once daily																	
	58.5kg and above	7mg once daily																	
Adult aged 18 years and over		Continue treatment at the stabilised dose																	

Specialist initiation and titration**Dose Titration Schedule for Children Aged 6-12 years**

For children aged 6 and above weighing < 25kg, initiate starting dose of 0.05 – 0.12mg/kg/day; adjust dose in increments of not more than 1mg per week according to the patient's response and tolerability. Max 4mg once a day.

Weight Group	Week 1	Week 2	Week 3	Week 4
25 kg and up Max Dose= 4 mg	1 mg	2 mg	3 mg	4 mg

Dose Titration Schedule for Adolescents (Aged 13-17 Years)/ Adolescent patients must weigh at least 34 kg.

Weight Group	Week 1	Week 2	Week 3	Week 4	Week 5	Week 6	Week 7
34-41.4 kg Max dose=4mg	1 mg	2 mg	3 mg	4 mg			
41.5-49.4 kg Max dose= 5mg	1 mg	2 mg	3 mg	4 mg	5 mg		
49.5-58.4 kg Max dose= 6mg	1 mg	2 mg	3 mg	4 mg	5 mg	6 mg	
58.5 kg and above Max dose= 7mg	1 mg	2 mg	3 mg	4 mg	5 mg	6 mg	7 mg

Adolescents weighing 58.5 kg and above may be titrated to a 7 mg/day dose after the patient has completed a minimum of 1 week of therapy on a 6 mg/day dose and the physician has performed a thorough review of the subject's tolerability and efficacy.

Dose reduction may be required in patients with different degrees of hepatic or renal impairment – please refer to current SPC for further information.

Ongoing prescribing

Shared Care may only be commenced following initiation, stabilisation and review of treatment. In addition, formal agreement must have been received from the primary care prescriber. Termination will be the responsibility of the specialist.

Review the use of guanfacine at least once a year and discuss with the patient (and their families and carers as appropriate) whether the medication should be continued (NICE NG87).

Consider trial periods of stopping medication or reducing the dose when assessment of the overall balance of benefits and harms suggests this may be appropriate. This will be undertaken and supervised by the specialist who will advise the patient and GP of the outcome.

For extended periods of treatment (over 12 months) the specialist should re-evaluate the usefulness of guanfacine every 3 months for the first year and then at least yearly based on clinical judgement.

<p>5. Baseline investigations, initial monitoring, and dose titration to be undertaken by specialist</p>	<p>Baseline: - Pre-treatment screening Before starting medication for ADHD, a full assessment should be completed which should include:</p> <ul style="list-style-type: none"> • a review to confirm they continue to meet the criteria for ADHD and need treatment • a review of mental health and social circumstances, including: <ul style="list-style-type: none"> ○ presence of coexisting mental health and neurodevelopmental conditions ○ current educational or employment circumstances ○ risk assessment for substance misuse and drug diversion ○ care needs • a review of physical health, including: <ul style="list-style-type: none"> ○ a medical history, taking into account conditions that may be contraindications for specific medicines ○ current medication ○ height and weight (measured and recorded against the normal range for age, height and sex) ○ baseline pulse and blood pressure ○ A cardiovascular assessment. <p>An electrocardiogram (ECG) is not needed before starting guanfacine, unless the person has any of the features mentioned in recommendation 1.7.5 of the NICE 2018 Attention deficit hyperactivity disorder diagnosis and management guidelines or a co-existing condition that is being treated with a medicine that may pose an increased cardiac risk.</p> <p><i>During dose titration, weekly monitoring for signs and symptoms of somnolence and sedation, blood pressure for hypotension and pulse for bradycardia, clinical response is required.</i></p>													
<p>6. Ongoing monitoring requirements to be undertaken by primary care</p>	<table border="1"> <thead> <tr> <th data-bbox="475 1171 933 1227">Monitoring</th> <th data-bbox="933 1171 1492 1227">Frequency</th> </tr> </thead> <tbody> <tr> <td data-bbox="475 1227 933 1424">Blood pressure and pulse (appropriate for age, using information supplied in attached request letter – children & adolescents only)</td> <td data-bbox="933 1227 1492 1424">At every adjustment of dose or specialist visit and then every 6 months Primary care – every 6 months</td> </tr> <tr> <td data-bbox="475 1424 933 1621">Weight (in adults); Height and weight (in children and adolescents)</td> <td data-bbox="933 1424 1492 1621">At every adjustment of dose or visit or at least every 6 months Primary care – every 6 months Weight every 3 months in children 10 years and under</td> </tr> <tr> <td data-bbox="475 1621 933 1677">Side effects</td> <td data-bbox="933 1621 1492 1677">Every 6 months</td> </tr> <tr> <td data-bbox="475 1677 933 1733">Compliance</td> <td data-bbox="933 1677 1492 1733">Every 6 months</td> </tr> <tr> <td data-bbox="475 1733 933 1776">Clinical need, benefits, side effects</td> <td data-bbox="933 1733 1492 1776">Annual review by Specialist</td> </tr> </tbody> </table>	Monitoring	Frequency	Blood pressure and pulse (appropriate for age, using information supplied in attached request letter – children & adolescents only)	At every adjustment of dose or specialist visit and then every 6 months Primary care – every 6 months	Weight (in adults); Height and weight (in children and adolescents)	At every adjustment of dose or visit or at least every 6 months Primary care – every 6 months Weight every 3 months in children 10 years and under	Side effects	Every 6 months	Compliance	Every 6 months	Clinical need, benefits, side effects	Annual review by Specialist	
Monitoring	Frequency													
Blood pressure and pulse (appropriate for age, using information supplied in attached request letter – children & adolescents only)	At every adjustment of dose or specialist visit and then every 6 months Primary care – every 6 months													
Weight (in adults); Height and weight (in children and adolescents)	At every adjustment of dose or visit or at least every 6 months Primary care – every 6 months Weight every 3 months in children 10 years and under													
Side effects	Every 6 months													
Compliance	Every 6 months													
Clinical need, benefits, side effects	Annual review by Specialist													
<p>Cardiovascular monitoring (blood pressure and heartrate) should be undertaken before and after each dose adjustment. Refer to ‘Adverse Drug Reactions’ section for advice and actions to be taken.</p>														
<p>7. Pharmaceutical aspects</p>	<p>Route of administration:</p>	<p>Oral</p>												
	<p>Formulation:</p>	<p>Prolonged release tablets in 1mg, 2mg, 3mg and 4mg</p>												

	Administration details:	<p>Tablets should be swallowed whole, and should not be administered with high fat meals, to avoid increased guanfacine exposure.</p> <p>The prolonged release properties will be lost by crushing, chewing or breaking tablets before swallowing. Guanfacine should not be administered together with grapefruit juice.</p>								
	Other important information:	<ul style="list-style-type: none"> • Patients/carers are advised not to discontinue guanfacine without consulting their specialist. • Blood pressure and pulse may increase following discontinuation of guanfacine. • Tapering guanfacine dosing during withdrawal is recommended to minimise these potential withdrawal effects. • Monitoring of blood pressure and pulse is recommended during dose downward titration. <p>Guanfacine is a prescription only medicine (POM). It is not a controlled drug.</p>								
8. Contraindications	Please note this does not replace the Summary of Product Characteristics (SPC) and should be read in conjunction with it.									
9. Significant drug interactions	For a comprehensive list consult the BNF or Summary of Product Characteristics									
10. Adverse effects and management	<p>For a comprehensive list consult the BNF or Summary of Product Characteristics.</p> <p>The occurrence of somnolence/sedation and hypotension is most prominent in the first few weeks of treatment and diminishes gradually thereafter.</p> <p><u>In children</u>, parents/patients will have been advised by the ADHD specialist to report any suspected side effects directly to them. GPs should refer any patients with suspected side effects to the ADHD specialist irrespective of the advice in the following table.</p> <p>Guanfacine is a black triangle drug. Any suspected adverse reaction should be reported to the MHRA via the “Yellow Card” scheme on http://yellowcard.mhra.gov.uk/</p> <table border="1"> <thead> <tr> <th>Adverse effect</th> <th>Management</th> </tr> </thead> <tbody> <tr> <td>Clinically concerning or persistent somnolence / sedation Severe and persistent headache Syncope</td> <td>Exclude other causes and seek ADHD specialist advice if appropriate.</td> </tr> <tr> <td>Depression</td> <td>Exclude other causes and seek immediate ADHD specialist advice if suicidal ideation becomes apparent.</td> </tr> <tr> <td>Bradycardia Significant changes in blood pressure (hypotension)</td> <td>Exclude other causes. Repeat monitoring (blood pressure and pulse) on another occasion by GP. If symptoms thought secondary to the drug, seek ADHD specialist advice if appropriate.</td> </tr> </tbody> </table>		Adverse effect	Management	Clinically concerning or persistent somnolence / sedation Severe and persistent headache Syncope	Exclude other causes and seek ADHD specialist advice if appropriate.	Depression	Exclude other causes and seek immediate ADHD specialist advice if suicidal ideation becomes apparent.	Bradycardia Significant changes in blood pressure (hypotension)	Exclude other causes. Repeat monitoring (blood pressure and pulse) on another occasion by GP. If symptoms thought secondary to the drug, seek ADHD specialist advice if appropriate.
Adverse effect	Management									
Clinically concerning or persistent somnolence / sedation Severe and persistent headache Syncope	Exclude other causes and seek ADHD specialist advice if appropriate.									
Depression	Exclude other causes and seek immediate ADHD specialist advice if suicidal ideation becomes apparent.									
Bradycardia Significant changes in blood pressure (hypotension)	Exclude other causes. Repeat monitoring (blood pressure and pulse) on another occasion by GP. If symptoms thought secondary to the drug, seek ADHD specialist advice if appropriate.									

Supporting information

	Weight gain or increased body mass index (BMI)	Exclude other causes and seek ADHD specialist advice if appropriate.
11. Advice to patients and carers	<p>The specialist will counsel the patient with regard to the benefits and risks of treatment and will provide the patient with any relevant information and advice, including patient information leaflets on individual drugs.</p> <p>The patient should be advised to report any of the following signs or symptoms to their GP without delay:</p> <ul style="list-style-type: none"> • Patient with emergent suicidal ideation or behaviour <p>In children, parents/patients will have been advised by the ADHD specialist to report the above signs or symptoms directly to them.</p> <p>WARNING: Guanfacine may have a moderate to severe effect on the ability to drive, use machines or cycling. Patients will be warned of these possible effects during treatment initiation and be advised that if affected, they should avoid these activities.</p>	
12. Pregnancy and breastfeeding	Seek specialist advice for prescribing decision.	
13. Specialist contact information	If stopping medication or require advice. Please refer to the shared care agreement appendix 2	
14. Additional information	Where patient care is transferred from one specialist service or GP practice to another, a new shared care agreement must be completed.	
15. References	<ol style="list-style-type: none"> 1. Bolea-Alamanac et al. Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: Update on recommendations from the British Association for Psychopharmacology <i>Journal of Psychopharmacology</i> 2014; 28(3): 179-203 2. NICE guidelines NG87 March 2018: Attention deficit hyperactivity disorder: diagnosis and management; https://www.nice.org.uk/guidance/ng87 3. NICE quality standard (QS39) 2013 (updated March 2018): Attention deficit hyperactivity disorder; https://www.nice.org.uk/guidance/qs39 4. Summary of Product Characteristics (Intuniv[®]), updated 02/07/19, accessed 12/08/19; https://www.medicines.org.uk/emc/product/5099/smpc 5. BNF for Children BNF British National Formulary - NICE 6. NICE ESNM70: ADHD in children and young people: guanfacine prolonged-release (Mar 2016); https://www.nice.org.uk/advice/esnm70/resources/attention-deficit-hyperactivity-disorder-in-children-and-young-people-guanfacine-prolongedrelease-pdf-1502681158970053 	
16. To be read in conjunction with the following documents	<ul style="list-style-type: none"> • Policy for shared care (Appendix 1) • Shared care agreement (Appendix 2) • RMO Shared Care for Medicines Guidance • NHSE/NHSCC guidance – items which should not be routinely prescribed in primary care: guidance for CCGs NHSE 2019 • NHSE policy- Responsibility for prescribing between Primary & Secondary/Tertiary Care NHSE 	

Appendix 1

Policy for Shared Care

Shared care is only appropriate if it provides an optimum solution for the patient, and it meets the criteria outlined in the Shared Care section of the Pan Mersey Definitions and Criteria for Categorisation of Medicines in the Pan Mersey Formulary [document](#).

- Prescribing responsibility will only be transferred when the specialist and the patient's GP agree that the patient's condition is stable.
- Before prescribing responsibilities are transferred to primary care, all information required by the shared care framework for the individual medicine has been provided to the patient's GP.
- Patients will only be referred to the GP once the GP has agreed to the shared care agreement and returned signed copies.

Inherent in any shared care agreement is the understanding that participation is at the discretion of the GP, subject to the availability of sufficient information to support clinical confidence.

Specialist Responsibilities in Shared Care

- To obtain patient informed consent for sharing of care between the specialist, primary care prescriber and patient. Consenting parties must have sufficient, accurate, timely information in an understandable form. Consent must be given voluntarily and must be documented in the patient's notes. Patients should be aware that shared care will not always be the best option for them. This is a mutual agreement between the specialist and primary care, which needs to be confirmed with the shared care agreement.
- To confirm the diagnosis.
- To confirm that the patient's care can be suitably maintained by primary care, following their medicine being optimised for approximately 3 months, with satisfactory investigation results.
- To initiate the medicine, prescribe, and monitor for toxicity and efficacy as described by the shared care framework until the patient is stabilised.
- To ensure the patient or their carer:
 - Is counselled with regard to the risks and benefits of the medicine.
 - Is provided with any necessary written information with regard to the individual medicine including patient information leaflets on individual drugs.
 - Provides informed consent when any medicine is prescribed for an off-label indication for any condition
- To be familiar with the shared care framework.
- To provide all information to the patient's GP as required by the shared care framework when prescribing responsibility is initially transferred and at any subsequent times as necessary for safe and effective treatment of the patient.
- Following the request to the patient's GP to initiate shared care; to ensure that the patient has an adequate supply of medication (usually 28 days) until shared care arrangements are in place. Further prescriptions will be issued if, for unforeseen reasons, arrangements for shared care are not in place at the end of 28 days. Patients should not be put in a position where they are unsure where to obtain supplies of their medication.
- To assess the patient regularly as necessary for the duration of therapy. The specialist will send a written summary within 14 days to the patient's primary care prescriber, confirm that ongoing treatment with the monitored medicine is appropriate and record test results on the patient-held monitoring booklet if applicable confirm the current dosage and clearly highlight any changes made both to the patient and in writing to the patient's primary care prescriber.
- The specialist team will:

Supporting information

- provide training, advice, and guidance (as appropriate) for primary care prescribers if necessary to support the shared care agreement
 - provide contact details for both working and non-working hours
 - supply details for fast-track referral back to secondary/specialist care
 - provide the patient with details of their treatment, follow up appointments, monitoring requirements and, where appropriate, nurse specialist contact details
- To review the patient promptly if required by the GP.
 - To meet any additional requirements as required by the individual medicine shared care framework.
 - To communicate the failure of a patient to attend a routine hospital review and advise the GP of appropriate action to be taken.
 - Following the addition of a new drug to an existing regime covered by a shared care agreement, the Specialist must initiate, prescribe, and monitor the new drug in accordance with the relevant shared care agreement including subsequent review and inform the GP of this. A new shared care agreement must then be initiated for the new drug.
 - Prior to transfer of prescribing, the specialist will ensure that patients (and their caregivers, where appropriate) are aware of and understand their responsibilities to attend appointments and the need for continued monitoring arrangements.

Primary Care Responsibilities in Shared Care

- To prescribe within their own level of competence.
- To reply to a written request for shared care within 21 days ensuring both copies of the shared care agreement are signed if appropriate.

If agreeing to shared care, the GP is asked:

- To prescribe, manage and monitor the medicine as advised by the specialist and in line with the individual shared care framework.
- To review the patient as required by the shared care framework
- To make appropriate and contemporaneous records of prescribing and/or monitoring and to note the existence of the shared care agreement on the patient's clinical record. A Snomed code "268529002 Shared Care- Specialist/GP" can be used. Where applicable, keep the patient-held monitoring record up to date with the results of investigations, changes in dose and alterations in management.
- To be familiar with the individual shared care framework, have the information and knowledge to understand the therapeutic issues relating to the patient's clinical condition and undergo any additional training if necessary.
- To report any adverse effect in the treatment of the patient to the specialist team, and via the MHRA Yellow Card Scheme <https://yellowcard.mhra.gov.uk/>.
- To inform the specialist of any relevant change in the patient's circumstances.
- To seek specialist advice as appropriate.
- To meet any additional requirements as required by the individual shared care framework.
- To respond to specialist communication relating to any change or addition to the patient's treatment or monitoring covered by the shared care agreement.
- Where community nurse involvement is required in the administration of medicines under a shared care framework, nurses should be provided with adequate information and guidance by the prescriber or the specialist. Arrangements should be made in good time for any potential problems to be resolved to ensure that patient care is not compromised

Where the GP wishes to withdraw prescribing, for example when the patient fails to attend for monitoring, they need to give the specialist team a minimum of 14 days' notice of their need to resume responsibility for prescribing. The specialist is required to acknowledge this request within the 14-day time period.

Patient Responsibilities in Shared Care

- To provide their informed consent for sharing of their care with the specialist and primary care prescriber. Consenting parties must have sufficient, accurate, timely information in an understandable and accessible format. Consent must be given voluntarily and must be documented in the patient's notes. Supporting information is available from NICE [Making decisions about your care](#)
- To take their medication as agreed, unless otherwise instructed by an appropriate healthcare professional.
- To meet all necessary monitoring arrangements to ensure the safe prescribing of their medication, and to alert the prescriber where these arrangements are not met.
- To attend all follow-up appointments with the primary care prescriber and specialist. If the patient is unable to attend any appointments, they should inform the relevant practitioner as soon as possible and arrange an alternative appointment.
- Inform healthcare professionals of their current medications, both prescribed and purchased elsewhere prior to receiving any new prescribed or over-the-counter medication.
- Report all suspected adverse reactions to medicines to their primary care prescriber.
- Store their medication securely away from children and according to the medication instructions.
- Read the information supplied by their primary care prescriber, specialist and pharmacist and contact the relevant practitioner if they do not understand any of the information given.

Appendix 2

Shared Care Request letter (Specialist to Primary Care Prescriber)

Request by specialist clinician for the patient's GP to enter into a shared care agreement

To be signed by consultant / prescribing member of specialist team (circle or underline as appropriate)

Dear *[insert Primary Care Prescriber's name]*

Patient name: *[insert patient's name]*

Date of birth: *[insert date of birth]*

NHS Number: *[insert NHS Number]*

Diagnosis: *[insert diagnosis]*

Please add patient addressograph
here

As per the agreed Pan Mersey APC shared care framework for *[insert medicine name and dose]* for the treatment of *[insert indication]*, this patient is now suitable for prescribing to move to primary care.

The patient fulfils criteria for shared care, and I am therefore requesting your agreement to participate in shared care. Where baseline investigations are set out in the shared care protocol, I have carried these out.

I can confirm that the following has happened with regard to this treatment:

	Specialist to complete
The risks and benefits of treatment have been explained to the patient	Yes / No
The patient has agreed to this shared care arrangement, understands the need for ongoing monitoring, and has agreed to attend all necessary appointments	Yes / No
A copy of the shared care framework which covers this treatment/the shared care framework can be found here <i>(insert electronic/ web link)</i>	Yes / No
I have provided the patient with sufficient medication to last until	
I have arranged a follow up with this patient in the following timescale	

If you have provided supporting information to the patient, please insert a copy here

Treatment was started on *[insert date started]* and the current dose is *[insert dose and frequency]*.

If you are in agreement, please undertake monitoring and treatment from *[insert date]* NB: date must be at least 1 month from initiation of treatment.

The next blood monitoring is due on *[insert date]* and should be continued in line with the shared care guideline.

Frequency of blood test:

I confirm that if this is a shared care agreement for a drug indication which is unlicensed or off label, informed consent has been received.

Please could you reply to this request for shared care and initiation of the suggested medication to either accept or decline within 14 days.

Supporting information

Details of Specialist Clinicians

Name Date

Consultant / prescribing member of specialist team (circle or underline as appropriate)

Signature

In all cases, please also provide the name and contact details of the Consultant.

When the request for shared care is made by a prescriber who is not the specialist, it is the supervising consultant who takes medico-legal responsibility for the agreement.

Consultant:

Contact details

Telephone number: Ext:

Address for return of documentation

.....

.....

Shared Care Agreement Letter (Primary Care Prescriber to Specialist)

Primary Care Prescriber Response

Dear *[insert Doctor's name]*

Patient *[insert Patient's name]*

NHS Number *[insert NHS Number]*

Identifier *[insert patient's date of birth and/or address]*

Thank you for your request for me to accept prescribing responsibility for this patient under a shared care agreement and to provide the following treatment

Medicine	Route	Dose & Frequency

I can confirm that I am willing to take on this responsibility from *[insert date]* and will complete the monitoring as set out in the shared care protocol for this medicine/condition.

Usual GP signature: Date

Usual GP name: (please print)

GP: Please sign and return a copy within 21 calendar days to the address above

GP Practice address/practice stamp

GP- If you do not agree to prescribe, please delete the section above and provide any supporting information as appropriate below: